Pirfenidone in idiopathic pulmonary fibrosis: The CAPACITY program

Expert Review of Respiratory Medicine

Volumn 5, Issue 4, 2011, Pages 473-481

  Richeldi, Luca ^a   Du Bois, Roland M ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

CAPACITY; future trends; idiopathic pulmonary fibrosis; pirfenidone; treatment

Indexed keywords

PIRFENIDONE; PLACEBO;

ANGINA PECTORIS; ANOREXIA; ARTHRALGIA; ARTICLE; BLADDER CANCER; BODY WEIGHT DISORDER; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FALLING; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH PROGRAM; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FAILURE; LABORATORY TEST; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; NAUSEA; OXYGEN SATURATION; PHOTOSENSITIVITY DISORDER; PHYSICAL EXAMINATION; PNEUMOTHORAX; RASH; RESPIRATORY FAILURE; SIDE EFFECT; SYNCOPE; THORAX PAIN; VOMITING;

EID: 80052614082     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.11.52     Document Type: Article

References (23)

1. Raghu G, Collard HR, Egan JJ et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183, 788-824 (2011).
2. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 168, 538-542 (2003). (Pubitemid 37088595)
3. Flaherty KR, Mumford JA, Murray S et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 168, 543-548 (2003). (Pubitemid 37088596)
4. King TE Jr, Safrin S, Starko KM et al. Analyses of efficacy end points in a controlled trial of interferon g-1b for idiopathic pulmonary fibrosis. Chest 127, 171-177 (2005). (Pubitemid 41724573)
5. Zappala CJ, Latsi PI, Nicholson AG et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur. Respir. J. 35, 830-836 (2010).
6. du Bois RM, Weycker D, Albera C et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. DOI: 0: 201011-1790OCv1 (2011) (Epub ahead of print).
7. du Bois RM, Albera C, Bradford WZ et al. Percent predicted forced vital capacity is a reliable, valid, and responsive measure of clinical status in patients with idiopathic pulmonary fibrosis (abstract). European Resp. Soc. Ann. Cong. (2010)
8. Raghu G, Brown KK, Bradford WZ et al. A placebo-controlled trial of interferon g-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 350, 125-133 (2004). (Pubitemid 38056223)
9. Demedts M, Behr J, Buhl R et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 353, 2229-2242 (2005). (Pubitemid 41697286)
10. Kubo H, Nakayama K, Yanai M et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128, 1475-1482 (2005). (Pubitemid 41324435)
11. King TE Jr, Behr J, Brown KK et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 177, 75-81 (2008).
12. Raghu G, Brown KK, Costabel U et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 178, 948-955 (2008).
13. King TE Jr, Albera C, Bradford WZ et al. Effect of Interferon g-1b on Survival in Patients With Idiopathic Pulmonary Fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374, 222-228 (2009).
14. Daniels CE, Lasky JA, Limper AH et al. Imatinib treatment for idiopathic pulmonary fibrosis. Randomized placebo-controlled trial results. Am. J. Respir. Crit. Care Med. 181, 604-610 (2010).
15. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW; Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N. Engl. J. Med. 12, 363, 620-628 (2010).
16. Noble PW, Albera C, Bradford WZ et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377, 1760-1769 (2011).
17. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-b gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 291, 367-373 (1999). (Pubitemid 29451612)
18. Azuma A, Nukiwa T, Tsuboi E et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 171, 1040-1047 (2005). (Pubitemid 40616955)
19. Taniguchi H, Ebina M, Kondoh Y et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 35, 821-829 (2010).
20. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 161, 646-664 (2000).
21. Spagnolo P, Del Giovane C, Luppi F et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 9, CD003134 (2010).
22. Collard HR. Idiopathic pulmonary fibrosis and pirfenidone. Eur. Respir. J. 35(4), 728-729 (2010).
23. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur. Respir. J. 35, 496-504 (2010).